Serotonin News and Research

Latest Serotonin News and Research

Maternal depression treated by SRIs can change the timing of language development in babies

Maternal depression and a common class of antidepressants can alter a crucial period of language development in babies, according to a new study by researchers at the University of British Columbia, Harvard University and the Child & Family Research Institute (CFRI) at BC Children's Hospital.

9 Oct 2012

Researchers discover brain mechanism responsible for sensation of nausea

Nausea is a common and distressing side effect of many drugs and treatments. Unlike vomiting, nausea is not well understood, but new research by University of Guelph scientists may soon change that.

6 Oct 2012

Fluoxetine increases offensive aggression and alters brain development in adolescent hamsters

Fluoxetine was the first drug approved by the FDA for major depressive disorder (MDD) in children and adolescents, and to this date, it remains one of only two selective serotonin reuptake inhibitors (SSRIs) registered for treatment of MDD in children and adolescents, despite reports that indicate this class of drugs is associated with side effects, such as agitation, hostility and aggression.

3 Oct 2012

Paroxetine shows promise against heart failure

A medication usually used to help treat depression and anxiety disorders has the potential to help prevent heart failure, according to researchers at the University of Michigan.

2 Oct 2012

Combination of two neuroprotective therapies shows promise against Alzheimer's

The combination of two neuroprotective therapies, voluntary physical exercise, and the daily intake of melatonin has been shown to have a synergistic effect against brain deterioration in rodents with three different mutations of Alzheimer's disease.

27 Sep 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Daytime oxygen link to poor sleep in COPD

Patients with chronic obstructive pulmonary disease experience poorer sleep quality than those without the disease, say the authors of an Irish study.

25 Sep 2012

Don’t take psychoactive drugs and drive

Taking benzodiazepines, antidepressants, and Z-drugs significantly increases the risk for a motor vehicle accident, report Taiwanese researchers.

21 Sep 2012

Mephedrone may cause memory loss

The party drug mephedrone can cause lasting damage to the brain, according to new research led by the University of Sydney.

19 Sep 2012

Kynurenic acid levels reduced in suicide attempters with schizophrenia

Cerebrospinal fluid concentrations of kynurenic acid are significantly lower in schizophrenia-spectrum patients with a history of suicide attempts than in those without, researchers report.

13 Sep 2012

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.

12 Sep 2012

Diet could avert toxic effects of quinine in patients with malaria

Scientists at The University of Nottingham say adverse side-effects caused by the anti-parasitic drug quinine in the treatment of malaria could be controlled by what we eat.

12 Sep 2012

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP).

5 Sep 2012